Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice
Main Authors: | Marin Kunimoto, Yasutomo Imai, Masako Matsutani, Minori Nakatani‐Kusakabe, Makoto Nagai, Masaru Natsuaki, Kiyofumi Yamanishi, Nobuo Kanazawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Journal of Cutaneous Immunology and Allergy |
Online Access: | https://doi.org/10.1002/cia2.12212 |
Similar Items
-
Dupilumab in atopic dermatitis patients with chronic hepatitis B
by: Masako Matsutani, et al.
Published: (2022-04-01) -
Real‐world use of dupilumab for 53 patients with atopic dermatitis in Japan
by: Masako Matsutani, et al.
Published: (2020-04-01) -
Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis
by: Kanako Kita, et al.
Published: (2023-06-01) -
Switching to ixekizumab improves adalimumab‐induced interstitial lung disease in patients with psoriatic arthritis: A case report
by: Hideki Hayashi, et al.
Published: (2021-02-01) -
IL-33-induced keratoconjunctivitis is mediated by group 2 innate lymphoid cells in mice
by: Yuka Hosotani, et al.
Published: (2023-04-01)